Disease-modifying approach to the treatment of alzheimers disease

From α-secretase activators to γ-secretase inhibitors and modulators

Francesco Panza, Vincenzo Solfrizzi, Vincenza Frisardi, Cristiano Capurso, Alessia D'Introno, Anna M. Colacicco, Gianluigi Vendemiale, Antonio Capurso, Bruno P. Imbimbo

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

In the last decade, advances in understanding the neurobiology of Alzheimers disease (AD) have translated into an increase in clinical trials assessing various potential AD treatments. At present, drugs used for the treatment of AD only slightly delay the inevitable symptomatic progression of the disease and do not affect the main neuropathological hallmarks of the disease, i.e. senile plaques and neurofibrillary tangles. Brain accumulation of oligomeric species of β-amyloid (Aβ) peptides, the principal components of senile plaques, is believed to play a crucial role in the development of AD. Based on this hypothesis, huge efforts are being made to identify drugs able to interfere with proteases regulating Aβ formation from amyloid precursor protein (APP). Compounds that stimulate α-secretase, the enzyme responsible for non-amyloidogenic metabolism of APP, are being developed and one of these, EHT-0202, has recently commenced evaluation in a phase II study. The discovery of inhibitors of β-secretase (memapsin-2, β-amyloid cleaving enzyme-1 BACE-1), the enzyme that regulates the first step of amyloidogenic APP metabolism, has proved to be particularly difficult because of inherent medicinal chemistry issues and only one compound (CTS-21166) has proceeded to clinical testing. Conversely, several compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, have been identified, the most advanced being LY-450139 (semagacestat), presently in phase III clinical development. There has been considerable disappointment over the failure of a phase III study of tarenflurbil, a compound believed to modulate the activity of γ-secretase, after encouraging phase II findings. Nevertheless, other promising γ-secretase modulators are being developed and are approaching clinical testing. All these therapeutic approaches increase the hope of slowing the rate of decline in patients with AD and modifying the natural history of this devastating disease within the next 5 years.

Original languageEnglish
Pages (from-to)537-555
Number of pages19
JournalDrugs and Aging
Volume26
Issue number7
DOIs
Publication statusPublished - 2009

Fingerprint

Amyloid Precursor Protein Secretases
Alzheimer Disease
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Amyloid
Amyloid beta-Protein Precursor
Amyloid Plaques
Enzymes
Amyloidogenic Proteins
Serum Amyloid A Protein
Neurofibrillary Tangles
Neurobiology
Pharmaceutical Chemistry
Pharmaceutical Preparations
Disease Progression
Peptide Hydrolases
Clinical Trials
Peptides
Brain

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Geriatrics and Gerontology

Cite this

Disease-modifying approach to the treatment of alzheimers disease : From α-secretase activators to γ-secretase inhibitors and modulators. / Panza, Francesco; Solfrizzi, Vincenzo; Frisardi, Vincenza; Capurso, Cristiano; D'Introno, Alessia; Colacicco, Anna M.; Vendemiale, Gianluigi; Capurso, Antonio; Imbimbo, Bruno P.

In: Drugs and Aging, Vol. 26, No. 7, 2009, p. 537-555.

Research output: Contribution to journalArticle

Panza, F, Solfrizzi, V, Frisardi, V, Capurso, C, D'Introno, A, Colacicco, AM, Vendemiale, G, Capurso, A & Imbimbo, BP 2009, 'Disease-modifying approach to the treatment of alzheimers disease: From α-secretase activators to γ-secretase inhibitors and modulators', Drugs and Aging, vol. 26, no. 7, pp. 537-555. https://doi.org/10.2165/11315770-000000000-00000
Panza, Francesco ; Solfrizzi, Vincenzo ; Frisardi, Vincenza ; Capurso, Cristiano ; D'Introno, Alessia ; Colacicco, Anna M. ; Vendemiale, Gianluigi ; Capurso, Antonio ; Imbimbo, Bruno P. / Disease-modifying approach to the treatment of alzheimers disease : From α-secretase activators to γ-secretase inhibitors and modulators. In: Drugs and Aging. 2009 ; Vol. 26, No. 7. pp. 537-555.
@article{ce154872a6dc41beb25fe11bf9a57fa9,
title = "Disease-modifying approach to the treatment of alzheimers disease: From α-secretase activators to γ-secretase inhibitors and modulators",
abstract = "In the last decade, advances in understanding the neurobiology of Alzheimers disease (AD) have translated into an increase in clinical trials assessing various potential AD treatments. At present, drugs used for the treatment of AD only slightly delay the inevitable symptomatic progression of the disease and do not affect the main neuropathological hallmarks of the disease, i.e. senile plaques and neurofibrillary tangles. Brain accumulation of oligomeric species of β-amyloid (Aβ) peptides, the principal components of senile plaques, is believed to play a crucial role in the development of AD. Based on this hypothesis, huge efforts are being made to identify drugs able to interfere with proteases regulating Aβ formation from amyloid precursor protein (APP). Compounds that stimulate α-secretase, the enzyme responsible for non-amyloidogenic metabolism of APP, are being developed and one of these, EHT-0202, has recently commenced evaluation in a phase II study. The discovery of inhibitors of β-secretase (memapsin-2, β-amyloid cleaving enzyme-1 BACE-1), the enzyme that regulates the first step of amyloidogenic APP metabolism, has proved to be particularly difficult because of inherent medicinal chemistry issues and only one compound (CTS-21166) has proceeded to clinical testing. Conversely, several compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, have been identified, the most advanced being LY-450139 (semagacestat), presently in phase III clinical development. There has been considerable disappointment over the failure of a phase III study of tarenflurbil, a compound believed to modulate the activity of γ-secretase, after encouraging phase II findings. Nevertheless, other promising γ-secretase modulators are being developed and are approaching clinical testing. All these therapeutic approaches increase the hope of slowing the rate of decline in patients with AD and modifying the natural history of this devastating disease within the next 5 years.",
author = "Francesco Panza and Vincenzo Solfrizzi and Vincenza Frisardi and Cristiano Capurso and Alessia D'Introno and Colacicco, {Anna M.} and Gianluigi Vendemiale and Antonio Capurso and Imbimbo, {Bruno P.}",
year = "2009",
doi = "10.2165/11315770-000000000-00000",
language = "English",
volume = "26",
pages = "537--555",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Springer International Publishing",
number = "7",

}

TY - JOUR

T1 - Disease-modifying approach to the treatment of alzheimers disease

T2 - From α-secretase activators to γ-secretase inhibitors and modulators

AU - Panza, Francesco

AU - Solfrizzi, Vincenzo

AU - Frisardi, Vincenza

AU - Capurso, Cristiano

AU - D'Introno, Alessia

AU - Colacicco, Anna M.

AU - Vendemiale, Gianluigi

AU - Capurso, Antonio

AU - Imbimbo, Bruno P.

PY - 2009

Y1 - 2009

N2 - In the last decade, advances in understanding the neurobiology of Alzheimers disease (AD) have translated into an increase in clinical trials assessing various potential AD treatments. At present, drugs used for the treatment of AD only slightly delay the inevitable symptomatic progression of the disease and do not affect the main neuropathological hallmarks of the disease, i.e. senile plaques and neurofibrillary tangles. Brain accumulation of oligomeric species of β-amyloid (Aβ) peptides, the principal components of senile plaques, is believed to play a crucial role in the development of AD. Based on this hypothesis, huge efforts are being made to identify drugs able to interfere with proteases regulating Aβ formation from amyloid precursor protein (APP). Compounds that stimulate α-secretase, the enzyme responsible for non-amyloidogenic metabolism of APP, are being developed and one of these, EHT-0202, has recently commenced evaluation in a phase II study. The discovery of inhibitors of β-secretase (memapsin-2, β-amyloid cleaving enzyme-1 BACE-1), the enzyme that regulates the first step of amyloidogenic APP metabolism, has proved to be particularly difficult because of inherent medicinal chemistry issues and only one compound (CTS-21166) has proceeded to clinical testing. Conversely, several compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, have been identified, the most advanced being LY-450139 (semagacestat), presently in phase III clinical development. There has been considerable disappointment over the failure of a phase III study of tarenflurbil, a compound believed to modulate the activity of γ-secretase, after encouraging phase II findings. Nevertheless, other promising γ-secretase modulators are being developed and are approaching clinical testing. All these therapeutic approaches increase the hope of slowing the rate of decline in patients with AD and modifying the natural history of this devastating disease within the next 5 years.

AB - In the last decade, advances in understanding the neurobiology of Alzheimers disease (AD) have translated into an increase in clinical trials assessing various potential AD treatments. At present, drugs used for the treatment of AD only slightly delay the inevitable symptomatic progression of the disease and do not affect the main neuropathological hallmarks of the disease, i.e. senile plaques and neurofibrillary tangles. Brain accumulation of oligomeric species of β-amyloid (Aβ) peptides, the principal components of senile plaques, is believed to play a crucial role in the development of AD. Based on this hypothesis, huge efforts are being made to identify drugs able to interfere with proteases regulating Aβ formation from amyloid precursor protein (APP). Compounds that stimulate α-secretase, the enzyme responsible for non-amyloidogenic metabolism of APP, are being developed and one of these, EHT-0202, has recently commenced evaluation in a phase II study. The discovery of inhibitors of β-secretase (memapsin-2, β-amyloid cleaving enzyme-1 BACE-1), the enzyme that regulates the first step of amyloidogenic APP metabolism, has proved to be particularly difficult because of inherent medicinal chemistry issues and only one compound (CTS-21166) has proceeded to clinical testing. Conversely, several compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, have been identified, the most advanced being LY-450139 (semagacestat), presently in phase III clinical development. There has been considerable disappointment over the failure of a phase III study of tarenflurbil, a compound believed to modulate the activity of γ-secretase, after encouraging phase II findings. Nevertheless, other promising γ-secretase modulators are being developed and are approaching clinical testing. All these therapeutic approaches increase the hope of slowing the rate of decline in patients with AD and modifying the natural history of this devastating disease within the next 5 years.

UR - http://www.scopus.com/inward/record.url?scp=70349093083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349093083&partnerID=8YFLogxK

U2 - 10.2165/11315770-000000000-00000

DO - 10.2165/11315770-000000000-00000

M3 - Article

VL - 26

SP - 537

EP - 555

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 7

ER -